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INTRODUCTION
At the beginning of hematopoietic stem cell transplanta-
tion (HSCT), clinical trials were carried out with the exclu-
sive use of pharmaceutical agents that were already approved
for other indications. Opportunities for testing investiga-
tional agents in studies sponsored by pharmaceutical manu-
facturers were limited. With the establishment of HSCT as
an accepted treatment for a variety of malignant and nonma-
lignant diseases, pharmaceutical manufacturers and academic
investigators have developed an increasing interest in testing
investigational new drugs and devices in this setting.
Reporting of adverse event (AE) data plays a crucial role
in the assessment of safety in clinical trials. The different
perspectives and cultures of clinical investigators, sponsors,
and regulatory agencies can cause considerable misunder-
standing about expectations and obligations concerning
AEs. This report reviews the historical background for clini-
cal trials in HSCT and summarizes federal regulations,
guidelines from the International Conference on Harmo-
nization (ICH), and standards from the National Cancer
Institute (NCI) for reporting AEs in clinical trials involving
investigational new drugs or devices. Difficulties with the
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application of the regulations, guidelines, and standards in
HSCT clinical trials are discussed, primarily from the per-
spective of investigators. Proposals are made for improve-
ment in reporting AE data in HSCT clinical trials. A more
sophisticated level of understanding by investigators might
help to identify opportunities and mechanisms for more
effective analysis of safety in HSCT clinical trials.
DIFFERING PERSPECTIVES ON ADVERSE EVENTS IN
HSCT CLINICAL TRIALS
Because HSCT can be a life-saving treatment for other-
wise incurable diseases, clinical investigators and patients are
prepared to accept a very high frequency of AEs in the over-
all assessment of risks and beneﬁts. AEs such as reversible
alopecia, mucositis, anorexia, nausea, vomiting, diarrhea,
fever, rash, fatigue, sleep disturbance, anemia, leukopenia,
thrombocytopenia, abnormal serum chemistries, and some
degree of temporarily impaired renal and hepatic function
occur in almost all patients who receive a myeloablative
preparative regimen for HSCT. Furthermore, predictable
permanent AEs such as infertility are acknowledged compli-
cations of such preparative regimens. In addition, HSCT
recipients are at risk of other less frequent complications, as
exempliﬁed by the admittedly atypical case history summa-
rized in the Appendix. In most published reports of results
from HSCT clinical trials, many of these AEs are essentially
ignored as “background,” and only selected AEs are given
overt attention.
Pharmaceutical manufacturers and regulatory agencies
have a different perspective on AEs in clinical trials. Unlike
clinical investigators, commercial sponsors and regulatory
agencies must pay considerable attention to all AE data in
clinical trials, because this information is needed to assess
the safety of investigational agents. This information must
be collected, analyzed, and reported in considerable detail
before an investigational agent can be licensed by regulatory
agencies. AE data are used to identify information needed
for the drug/product label that is published in package
inserts, advertisements, and the Physicians’ Desk Reference.
This information includes contraindications, warnings, pre-
cautions, drug interactions, and adverse reactions and is
sometimes accompanied by summaries of AE data from ran-
domized clinical trials.
FEDERAL REGULATIONS FOR SPONSORS AND
INVESTIGATORS
The Code of Federal Regulations (CFR) deﬁnes separate
responsibilities for sponsors and investigators with respect to
AEs that occur during the premarket development of new
drugs. The CFR also gives considerable attention to distinc-
tions between expedited reports and routine reports.
Sponsors are required to provide expedited reports to
the Food and Drug Administration (FDA) for all AEs that
are both “unexpected” and “serious” whenever there is a
reasonable possibility that the serious AE (SAE) may have
been caused by the study drug [1]. In this regulation, the
terms unexpected and serious have highly technical defini-
tions. The term unexpected means that the nature or severity
of an AE is not consistent with information in the study-
drug brochure. The term serious means that the AE caused
death or a threat to life, hospitalization or prolongation of
hospitalization, persistent or significant disability or inca-
pacity, or congenital anomaly or birth defect. Important
medical events that might not result in death, be life threat-
ening, or require hospitalization may be considered in the
SAE category when, based on appropriate medical judg-
ment, they jeopardize the patient and require medical or
surgical intervention to prevent one of the outcomes listed
in this deﬁnition.
Sponsors are also required to provide an annual report
providing a “narrative or tabular summary showing the most
frequent and most serious adverse experiences by body sys-
tem” [2]. This regulation requires reporting of AEs regard-
less of whether or not they are caused by the study drug, and
the term serious in this regulation appears to have a conven-
tional meaning.
Investigators are required to report promptly to spon-
sors any AE that may be reasonably regarded as caused by,
or probably caused by, the study drug [3]. There is no indi-
cation that investigators are required to report any AEs that
are considered to be independent of the study drug. At the
same time, however, investigators are required to maintain
adequate and accurate case histories that record all observa-
tions and other data pertinent to the investigation [4]. Case
histories include the case-report form, medical records, and
consent forms, but regulations do not deﬁne information to
be included in the case-report form. Investigators are also
required to report to the Institutional Review Board (IRB)
all unanticipated problems involving risk to human subjects.
Federal regulations provide little additional guidance
with respect to the content in reports of safety data by spon-
sors and investigators during the premarket phase of devel-
opment. The FDA MedWatch form used for premarket
reporting of SAEs and postmarketing surveillance reporting
of AEs, however, includes a set of checkboxes indicating the
reasons that qualify an AE as serious, space for a description
of the AE, a set of checkboxes indicating whether the AE
abated after use of the drug was stopped or the dose was
reduced, and a set of checkboxes indicating whether the AE
reappeared after reintroduction of the drug. The report
does not request information about severity, the date of res-
olution, or treatment for the AE.
A GAP IN EXPECTATIONS FOR INVESTIGATORS AND
SPONSORS?
Fulﬁllment of obligations by the investigator adequately
supports the sponsor’s obligations to provide expedited
reports for unexpected SAEs to the FDA, but reporting
limited to AEs caused by the study drug does not support
the sponsor’s obligations to provide an annual report sum-
marizing the most frequent and most serious adverse expe-
riences. In theory, sponsors could examine the medical
records to obtain the necessary AE data. In fact, sponsors
are obligated to make an independent review, especially in
multicenter trials that exceed the direct purview of any sin-
gle investigator. Because the sponsor’s own reviews may be
perceived as subject to bias, most sponsors ask investigators
to provide a complete tabulation of all AEs for each patient
in a case-report form, with condensed detail comparable to
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or exceeding what might be expected for reporting AEs on
the MedWatch form.
ICH GUIDELINES COMPARED TO FEDERAL REGULATIONS
The ICH of Technical Requirements for Registration of
Pharmaceuticals for Human Use is a joint effort by the
United States, the European Union, and Japan to develop a
single set of guidelines that will enable licensing of new
drugs in all participating countries. Unlike federal regula-
tions, ICH guidelines provide an explicit definition for an
AE. ICH guidelines deﬁne an AE as any untoward medical
occurrence in a patient or clinical investigation subject after
administration of a pharmaceutical product; the occurrence
does not necessarily have to have a causal relationship with
the treatment [5,6]. The guidelines go on to explain that an
AE can be any unintended sign (including an abnormal lab-
oratory ﬁnding), symptom, or disease temporally associated
with the use of an investigational medicinal or pharmaceuti-
cal product (herein termed study drug).
Expedited Reports
ICH guidelines concerning requirements for expedited
reporting of unexpected SAEs by sponsors are almost identical
to FDA requirements, but ICH guidelines for investigators are
much more demanding than those in federal regulations. First,
according to the ICH Guideline for Good Clinical Practice
[6], investigators must provide expedited reports of all SAEs to
sponsors, except for SAEs identiﬁed in the protocol, whereas
the FDA requires investigators to report only unexpected AEs
and the AEs (and SAEs) that might reasonably be caused by
the study drug. Second, the ICH Guideline for Clinical Safety
Data Management [5] deﬁnes the information to be included
in expedited reports of SAEs. In addition to the details
required by the FDA for MedWatch reports, the ICH guide-
line requires reporting of information about the date of reso-
lution for the AE, the setting in which the AE occurred, and
the outcome, including any treatment that was needed.
Routine Reports
The ICH Guideline for Good Clinical Practice [6] indi-
cates that investigators should report to the sponsor all AEs
and laboratory abnormalities identified in the protocol as
“critical” to safety evaluations of the study drug, in addition
to expedited reporting of all SAEs. This guideline does not
define critical or any other obligations for investigators in
routine reporting of AEs. The ICH Guideline for Structure
and Content of Clinical Study Reports [7], however, gives
sponsors a detailed set of expectations for summarizing non-
serious AEs in reports to regulatory agencies. Verbatim lan-
guage from this guideline is frequently incorporated into
clinical trial protocols. The structure of AE pages in case-
report forms is often dictated by this guideline and typically
contains the following items:
• Name of the AE, which may later be summarized
according to a dictionary of preferred terms;
• Onset date and resolution date, from which the duration
of the AE can be calculated;
• Severity, which may be measured according to one of sev-
eral international scales, such as the NCI common toxic-
ity criteria or World Health Organization toxicity scale;
• Causal relationship to study drug, defined in a study-
speciﬁc manner without standardization;
• Actions taken to treat the AE with respect to the admin-
istration of study drug (discontinuation, dose reduction,
temporary interruption, none);
• Other treatment (none, change in another medication,
addition of another medication);
• Outcome (resolved, improved, unchanged, worsened,
hospitalization, death);
• Whether the AE was serious, according to the technical
deﬁnition.
As discussed in the case history summarized in the Appen-
dix, documentation of this information entails compilation
of as many as 8 or 9 data items for each AE.
UTILITY OF ICH GUIDELINES FOR HSCT CLINICAL TRIALS
The ICH guidelines work best when AEs associated
with the underlying illness and concomitant treatments are
infrequent and distinct in character from AEs caused by the
study drug, when testing is conducted in an outpatient set-
ting with deﬁnable visits under conditions in which hospi-
talization is unexpected, and when new AEs are expected to
occur within a defined time frame after administration of
the study drug. These 3 conditions rarely apply to clinical
trials in HSCT. The underlying disease and related treat-
ment require frequent hospitalization and always cause a
large number of AEs, most often related to the pretrans-
plantation conditioning regimen, posttransplantation
immunosuppressive treatment, graft-versus-host disease, or
infections. Many of these AEs have a remitting and relaps-
ing course with variable severity across time periods rang-
ing from months to years, making it difficult to separate
different episodes from each other or to define a date of
resolution.
The ICH guidelines require a high level of detail in
reporting all AE data, without regard for the severity of the
AE or its perceived relationship to the study drug. In the
context of HSCT, indiscriminate reporting of all AEs carries
enormous expense and provides a very low “signal-to-noise”
ratio. In fact, the overwhelming amount of information can
make it difﬁcult to discern the AEs that are truly associated
with the study drug, unless comparisons can be made in a
placebo-controlled trial.
SUMMARY OF NCI STANDARDS FOR REPORTING AE DATA
The Cancer Therapy Evaluation Program (CTEP) at
NCI has developed standards for reporting AE data in can-
cer treatment clinical trials with investigational agents sup-
plied under an NCI-sponsored IND [8]. These standards
were developed with the involvement of the FDA and were
designed to comply with relevant regulations. Every attempt
was made to deﬁne the minimum number of data elements
needed to fulﬁll the regulatory, scientiﬁc, and administrative
needs of the NCI.
The Common Toxicity Criteria (CTC) developed by
the NCI provide a scaled listing of the AEs most frequently
encountered in cancer clinical trials, and provisions are
made for the special needs of trials that involve HSCT [9].
Scales for AEs that cause symptoms have been developed in
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accord with the degree of disability, and scales for AEs that
do not cause disability have been developed in accord with
the degree of threat to life and requirement for medical
intervention.
The CTC Manual also provides deﬁnitions for attribu-
tion of AEs [8]. According to the deﬁnitions, the term deﬁ-
nitely indicates that the AE is clearly related to the study
drug. The term probably indicates that the AE is likely
related to the study drug. The term possibly indicates that the
AE may be related to the study drug. The term unlikely indi-
cates that it is doubtful that the AE is related to the study
drug. The term unrelated indicates that the AE is clearly not
related to the study drug. The deﬁnitions provide no further
guidance concerning the criteria that one might use in
assessing causal relationships between the AE and the use of
the study drug, and the distinctions between possibly, proba-
bly, and deﬁnitely have no procedural signiﬁcance in deciding
whether an AE should be reported.
According to the NCI guidelines [10], investigators are
expected to provide expedited reports of all grades 4 and 5
AEs, whether expected or not, in all trials (Table 1). In addi-
tion, investigators are expected to provide expedited reports
of all unexpected grades 2 and 3 AEs that were possibly,
probably, or definitely caused by the drug, regardless of
whether or not the AE can be considered serious. Finally,
investigators are expected to provide expedited reports of all
grade 3 AEs that were possibly, probably, or definitely
caused by the drug and resulted in hospitalization or prolon-
gation of hospitalization, whether expected or unexpected.
The NCI standards for routine reports vary according
to the type of trial under consideration and the type of AE.
In early phase I studies, investigators are required to report
all AEs, regardless of their severity, whether they are serious
or not, and whether expected or unexpected. In late phase I
trials and phase II trials, investigators are required to report
all grades 4 (life-threatening) and 5 (fatal) AEs and all AEs
that are possibly, probably, or deﬁnitely attributable to the
study drug. In phase III trials, investigators are required to
report only SAEs.
The CTEP generic data form for routine (nonexpe-
dited) reporting of AE information includes a template list
of preprinted AEs that commonly occur during treatment
for cancer, with space for listing additional AEs that are not
included. Space is provided for the date of onset, and check-
boxes are included to indicate the severity of the AE and the
attribution. The form does not include the resolution date
or any information about actions taken with respect to the
administration of the study drug or other treatment for the
AE. AEs that occur on more than 1 occasion are reported
only once within each cycle of treatment, and AEs that recur
with similar severity in subsequent cycles are not reported.
This form for reporting AEs is considerably simpliﬁed com-
pared to those designed by commercial sponsors in response
to ICH guidance.
UTILITY OF NCI STANDARDS AS APPLIED TO HSCT TRIALS
Use of standardized severity scales will have a major
advantage in decreasing variability in reporting AE data in
clinical trials involving HSCT, thereby facilitating compar-
isons among different single-center studies and improving
the consistency of AE data within multicenter trials. The
NCI standards for expedited reports appropriately ignore all
grade 1 AEs. Expedited reporting of all unexpected grades 2
and 3 AEs that might be related to the study drug and all
expected AEs possibly related to the study drug and result-
ing in hospitalization can facilitate early detection of poten-
tially important safety information. In beginning to calibrate
the amount of reported information according to AE sever-
ity, the NCI has identiﬁed one path toward more efﬁcient
and effective collection of AE data in clinical trials.
The NCI standards for expedited reports and the stan-
dards for phase II studies suffer from too much reliance on
the investigator’s ability to distinguish AEs caused by the
study drug from those that are not caused by the study drug.
In addition, limiting AE reports to those caused by the study
drug in phase II studies would not allow an increased fre-
quency of grades 1 to 3 AEs to be detected if the AE occurs
with any appreciable frequency after HSCT in the absence
of the study drug (eg, liver toxicity). Investigators would
most likely attribute such AEs to the transplantation and
would therefore elect not to report AEs of this type, except
as required for early phase I trials. This approach precludes
any ability to determine whether the frequency or severity
of these AEs is increased among patients treated with the
study drug in a controlled trial.
Table 1. NCI Standards for Reporting AE Data*
Severity Grade
1 2 3 4 to 5
Attribution Unexpected Expected Unexpected Expected Unexpected Expected Unexpected Expected
Unrelated 1A 1A 1A 1A 2A 2A 3 3
Unlikely 1A 1A 1A 1A 2A 2A 3 3
Possible 1AB 1AB 3 2AB 3 2AB 3 3
Probable 1AB 1AB 3 2AB 3 2AB 3 3
Definite 1AB 1AB 3 2AB 3 2AB 3 3
*Numbers in the table indicate requirements for reporting of AEs as follows. 1, Expedited reporting is not required in any study. 2, Expedited
reporting is required whenever the AE results in hospitalization or prolongation of existing hospitalization. 3, Expedited reporting is required,
except for expected grade 4 myelosuppression in phase II and phase III studies. A, Routine (nonexpedited) reports are required for AEs in early
phase I trials. B, Routine (nonexpedited) reports are required for late phase I and phase II studies.
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The application of greatest scrutiny during early studies
and progressively less scrutiny for more advanced studies is
not well suited to HSCT trials. Highly detailed AE data
from an early phase study cannot be easily interpreted,
because a high proportion of AEs will be caused by the
underlying disease and by concomitant treatment, especially
in patients with end-stage disease. In HSCT trials, adverse
reactions related to a study drug can be identiﬁed reliably
only by an increase in severity or frequency of a particular
AE among subjects who received the study drug compared
to those who received placebo or alternative treatment in a
controlled clinical trial.
POTENTIAL FOR NEGOTIATION IN PLANNING FOR AE
REPORTING
In October 2001, the FDA issued a guidance document
for industry entitled Cancer Drug and Biological Products—
Clinical Data in Marketing Applications [11] that provided
recommendations for sponsors designing clinical trials to
demonstrate the safety and efficacy of cancer treatments.
This guidance emphasizes the need to report all grades 3 to
5 “toxicity” in all studies. Data on SAEs associated with the
use of a drug and AEs leading to discontinuation or dose
reduction should always be collected. With allowance for
these exceptions, the guidance suggests that it might not be
necessary to report grades 1 to 2 toxicity for all patients,
provided that this information is available for an adequate
number of patients from at least 1 study. In large studies,
detailed information about grades 1 to 2 toxicity from a
subset of patients might be sufﬁcient. Preplanned collection
of data describing the incidence of grades 1 to 2 toxicity
may be needed to make a risk-beneﬁt assessment for drugs
known to have speciﬁc toxicity, if the drug is anticipated to
provide only marginal clinical benefit. The guidance also
emphasizes that information about the duration, actions
taken (eg, treatment delayed, dose reduced, patient hospi-
talized), and resolution of toxicity should be included in
each report.
The guidance document emphasizes the need for a care-
fully considered safety analysis plan in all studies. Thor-
oughly justified deviations from complete collection of all
AE information from every patient can be allowed after dis-
cussion and agreement with the FDA. As a parenthetical
comment, the term toxicity might cause confusion by imply-
ing that AEs need not be reported unless there was a causal
relationship with the study drug. To avoid such confusion,
the term adverse event might be preferable.
PROPOSALS FOR IMPROVEMENT IN REPORTING AE
DATA IN HSCT CLINICAL TRIALS
The following measures might improve the efﬁciency and
effectiveness of AE data collection in HSCT clinical trials.
(1) A standardized template of organ systems and severity scales
should be adopted, with allowances for ad hoc additions and
modiﬁcations as needed for speciﬁc study drugs. For this pur-
pose, the NCI Common Toxicity Scale would serve as a
useful working model. In this scale, the guiding deﬁni-
tions for each grade of severity are calibrated to the level
of discomfort experienced by subjects and the degree of
interference with normal everyday activities or to the
level of threat to life or requirement for medical inter-
vention. To avoid subjective interpretation, protocols
should not quote the guiding deﬁnitions. Instead, proto-
cols should refer directly to a standard document sum-
marizing the detailed severity scales for each AE.
(2) Preprinted lists of certain AEs that occur frequently after
HSCT should be used as an integral part of the case-report
form. This recommendation might help to improve the
degree of uniformity in reporting AE information in
multicenter studies.
(3) Standardized and detailed definitions of causality relation-
ships between study-drug administration and AEs should be
adopted. The following deﬁnitions might serve as a use-
ful starting point.
Probably related: The AE is not likely to be caused by
the subject’s underlying medical condition or other
concomitant therapy, and the nature of the AE or the
temporal relationship between the onset of the AE and
study-drug administration leads the investigator to believe
that there is a reasonable chance of a causal relationship.
Possibly related: The AE could be attributed to the
subject’s underlying medical condition or other con-
comitant therapy, but the nature of the AE or the tem-
poral relationship between the onset of the AE and
study-drug administration leads the investigator to
believe that there could be a causal relationship.
Not related: The AE is most plausibly explained by
the subject’s underlying medical condition or concomi-
tant therapy, or the AE has no plausible temporal rela-
tionship to the study drug, or the AE has no biologically
plausible relationship to the study drug.
(4) Requirements for expedited reporting of SAEs by investigators
should be modiﬁed. Expedited reporting of hospitalization
or prolongation of hospitalization should be required
only when related or possibly related to the study drug,
because hospitalization is more often the rule rather
than the exception for subjects who are participating in
clinical trials involving HSCT. For purposes of expe-
dited reporting of SAEs, the terms persistent or signiﬁcant
should be understood more as permanent or irreversible
in describing disability or incapacity, because all subjects
who participate in clinical trials involving HSCT experi-
ence some degree of temporary disability and incapacity.
In this circumstance, the terms persistent or signiﬁcant do
not provide useful guidance as a standard. Certain irre-
versible AEs, such as infertility, should be exempt from
reporting as SAEs.
(5) The level of detail in reporting AE data should be calibrated
to the severity of the AE and its perceived relationship to the
Table 2. Proposed Levels of Detail for AE Reporting*
Severity
Relatedness 1 2 3 4 5
Not related 1 1 2 3 3
Possibly related 2 2 2 3 3
Related 2 2 2 3 3
*Numbers in the table refer to the level of detail proposed for
reporting AE data. Deﬁnitions for each level of detail are provided in
the text.
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study drug. Table 2 exemplifies one possible model for
consideration.
Level 1 detail reports the name of the AE, the date
of first onset, peak severity, and relationship to study
drug. Multiple recurrences of the same AE are reported
together. It is assumed that these events were treated
appropriately and eventually resolved in a manner con-
sistent with the underlying disease and concomitant
treatment. By deﬁnition, events reported at this level of
detail were not disabling, life threatening, or fatal and
did not prompt any alteration in the administration of
the study drug.
Level 2 detail includes all of the data for level 1 and
also reports the resolution date and actions taken with
respect to administration of the study drug and other
treatment for the AE. Multiple recurrences of the same
AE are reported separately.
Level 3 detail includes all of the data for level 2 and
also requires expedited reporting to the IRB and spon-
sor, equivalent to the requirements for an SAE.
Any AE prompting a change in the administration
of the study drug should be reported at level 2 or level 3
detail, and all SAEs must be reported at level 3 detail.
This recommendation is intended to decrease time-
intensive attention to the very large number of AEs with
low severity or a high likelihood of being caused by the
underlying disease or related treatment and to encour-
age more thoughtful attention to AEs with higher sever-
ity or higher likelihood of being caused by the study
drug. Considerable time and effort will be saved by not
requiring clinical trial staff to rewrite the entire list of all
ongoing and recurring AEs at each evaluation. Decreas-
ing this repetition will give clinical staff greater motiva-
tion to follow a required schedule of evaluations and
procedures for reviewing and recording AEs in hospital-
ized subjects, instead of relying on retrospective review
of the medical record. This recommendation does not
in any way interfere with the ability to determine the
population frequency or peak severity distribution of
any AE, because all AEs are reported. Implementation
of this recommendation will require education and
training to assure consistency of reporting. For this pur-
pose, it would be of interest to create a realistic set of
“medical records” or “source documents” for hypotheti-
cal HSCT patients as an objective feasibility test of this
approach as opposed to the traditional standard.
(6) The time period of monitoring for AEs should be calibrated to
the severity of the AE and its perceived relationship to study
drug. The time period of monitoring for AEs that qual-
ify for level 1 reporting should be speciﬁed in the proto-
col and may be defined by biological plausibility. For
example, febrile reactions associated with infusion of a
study drug might qualify for reporting only if they occur
within 24 hours after administration, unless there is rea-
son to believe that delayed reactions can occur. The
time period of monitoring for AEs that qualify for level
2 or level 3 reporting should extend for the entire dura-
tion of the study.
(7) Investigators should be encouraged to report AEs as diseases or
syndromes, wherever possible, instead of reporting individual
component symptoms, signs, laboratory abnormalities, and
sequelae. For example, pneumonitis should be reported
as a single entity rather than reporting cough, tachyp-
nea, rales, pulmonary inﬁltrates, and hypoxia separately.
Medical consequences of AEs should be identified as
part of the syndrome. This approach is designed to
streamline the review and to facilitate the interpretation
of AE data. Close oversight by an experienced physician,
physician assistant, or nurse practitioner is necessary,
because other medical professionals are generally not
trained to make diagnostic interpretations.
(8) If laboratory abnormalities will be screened and evaluated sep-
arately as part of the safety surveillance plan, they should not
be reported as AEs, unless a causal relationship with the study
drug is suspected. The case summarized in the Appendix
illustrates the potential impact that this recommendation
might have. Collection of results directly from the labo-
ratory through a computer interface will enhance accu-
racy and completeness. This recommendation will assure
a uniform, standardized analysis of severity grade and
duration for all laboratory abnormalities. At the same
time, reporting as an AE when a causal relationship with
the study drug is suspected will enable collection of per-
tinent information about actions taken to correct the
abnormality; this information would be lost if the analy-
sis relied entirely on the laboratory reports.
(9) Certain AEs should be exempt from mandatory reporting in
HSCT clinical trials. The most obvious examples are infer-
tility and alopecia, unless hair growth does not return.
CONCLUSIONS
For the most part, clinical investigators have little difﬁ-
culty with expedited reporting of unexpected SAEs in HSCT
trials, and, with a few modiﬁcations, there would be little dif-
ficulty in accepting expedited reporting of all SAEs. As
pointed out previously [12], however, even well-intentioned
and highly motivated clinical investigators have considerable
difﬁculty in attempting to meet the expectations imposed by
sponsors when standard AE reporting is driven more by
overinterpretation of regulations than by a specific safety
surveillance plan. Investigators easily recognize that all-
inclusive reporting of AEs in clinical trials involving severely
ill subjects can solicit so much noise that the true safety pro-
ﬁle of an investigational product never really emerges [12].
For those in the trenches of conducting clinical trials,
attempting to collect too much AE information creates disin-
centives and problems that are easily underestimated by
sponsors and regulatory agencies. Progress in resolving these
issues can continue only through the joint efforts of inter-
ested investigators, sponsors, and regulatory agencies.
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APPENDIX
An Illustrative Case Report
A 25-year-old man was diagnosed with acute lym-
phoblastic leukemia. After induction therapy, the disease
remained in remission until 5 years later, when results of a
routine bone marrow biopsy showed 33% blasts. There was
no response after treatment with hyperfractionated cyclo-
phosphamide, vincristine, doxorubicin, and dexamethasone
(hyper-CVAD) chemotherapy and only a 2-month response
after treatment with liposomal vincristine, methotrexate,
and L-asparaginase. Results of a marrow biopsy showed
90% blasts after further treatment with clofarabine, vin-
cristine, hydroxyurea, and 6-mercaptopurine. The only
available donor was an HLA-haploidentical brother who
was HLA-A, B, and DR-mismatched. Both the patient and
the donor were Epstein-Barr virus and cytomegalovirus
(CMV) seropositive. An investigational new device was used
to treat donor cells. AEs for this patient were recorded from
the initiation of the conditioning regimen to day 100 after
the transplantation.
The patient received an 8-day conditioning regimen
consisting of high-dose cyclophosphamide, thiotepa, and
fractionated total body irradiation. During conditioning, the
patient experienced 14 AEs, which included chills, fever,
insomnia, nausea, grades II to III anemia, vomiting,
headache, sinus congestion, thrombocytopenia, coagulase-
negative staphylococcus bacteremia, grades III to IV
hyperglycemia, grades III to IV neutropenia, diarrhea, and
indigestion. With 8 data points reported for each AE as
required by ICH guidelines, these 14 AEs account for a total
of 112 data points during an 8-day period.
On the day of transplantation, the patient experienced
E. coli bacteremia, chills, constipation, mucositis, intermit-
tent ecchymosis, intermittent tachycardia, and grade II
thrombocytopenia. During the ﬁrst 4 weeks after the trans-
plantation, 45 AEs encompassing 315 data points were
recorded: grade III thrombocytopenia, intermittent fever,
fatigue, intermittent cough, bilateral lower-extremity
edema, enterococcus bacteremia, mucositis, folliculitis,
intermittent diarrhea, abdominal pain, petechiae, hypo-
kalemia, grades II to III skin graft-versus-host disease
(GVHD), hand edema, pericardial effusion, intermittent
nose bleed, intermittent restlessness, intermittent hyperten-
sion, decreased serum phosphate, anemia, alterations in
taste, intermittent tremors, dry eyes, cystitis, pain at the
soles of the feet, intermittent anxiety, bilateral foot edema,
coagulase-negative staphylococcus urinary tract infection,
perineal excoriation, dysuria, bladder spasm, hepatic GVHD
(grade I), penile ulceration, mucositis, coagulase-negative
staphylococcus eye infection, weight loss, penile pain, hema-
turia, urinary hesitancy, CMV antigenemia, grade II ocular
GVHD, blurred vision, and bladder pain. Two of these AEs
(acute GVHD and hemorrhagic cystitis) were considered
serious by regulatory deﬁnition.
On study day 30, the patient was hospitalized for hem-
orrhagic cystitis. At the time of admission, the platelet count
was 17 × 109/L, the serum glucose was 349 mg/dL, and the
serum creatinine was increased. The patient had intermit-
tent nausea, grade II skin GVHD, and anorexia. The urinal-
ysis showed >100 erythrocytes per high-power ﬁeld. Blood,
urine, and stool cultures were negative for bacteria and
viruses. The patient initially received 2 units of packed red
blood cells and 6 units of pooled platelets. Platelet transfu-
sions were then administered every 12 hours to maintain
the platelet count above 50 × 109/L. On study day 31, AEs
included depression, urinary hesitancy, bone pain, and
constipation. On study day 32, additional AEs included
coagulase-negative staphylococcus bacteremia, intermittent
diarrhea, abdominal pain, perineal excoriation, and dry lips.
On study day 33, the patient was transferred to the intensive
care unit with hypotension and hematemesis secondary to
severe esophagitis, gastritis, and vomiting. Additional AEs
included anemia, fibrosis of stomach, and musculoskeletal
weakness. After 24 hours, the patient was transferred back to
the inpatient unit. On study day 38, blood cultures were
positive for CMV. Hemorrhagic cystitis increased in sever-
ity, requiring the initiation of continuous bladder irrigation
on study day 39.
During this hospitalization, the patient experienced
fever, radiographic opacity in the lung bases on both sides,
cough, hypokalemia, positive stool culture, intermittent
drowsiness, chills, abdominal pain, penile pain, balanitis,
bilateral rhonchi, intermittent bladder spasms, hepatic
GVHD, splenomegaly, and hypotension. Chest computed
tomography on study day 53 showed a large pericardial effu-
sion, and an echocardiogram on study day 56 showed a 50%
to 59% left ventricular ejection fraction and a small persis-
tent pericardial effusion. On study day 55, the severity of
hemorrhagic cystitis increased to grade IV, and cystoscopy
revealed extensive edema, erythema, adherent clots, and
bilateral vesicoureteral reflux. The patient subsequently
experienced extraperitoneal bladder perforation and
hypotension. Bilateral nephrostomy tubes were placed for
urinary diversion.
The patient remained hospitalized during the remaining
100-day follow-up period. Other AEs included edema, bilat-
eral extremity edema, mucositis, hypokalemia, fever, weight
loss, bacteremia, renal blood clots, hypertension, epistaxis,
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positive stool culture, elevated serum creatinine, altered
mental status, bilateral hydronephrosis, candidemia,
hyponatremia, hypocalcemia, hypophosphatemia, gastroin-
testinal hemorrhage, musculoskeletal weakness, diarrhea,
dysuria, neutropenia, persistent skin wound, ﬂuid overload,
CMV antigenemia, vomiting, and perineal excoriation.
A total of 172 AEs encompassing 1376 data points were
reported during this observation period, not including
information about the medications used to manage these
events, the blood transfusion records, and vital-sign data
collected to support the recording of AEs. If reports of
changes in objective data (laboratory values and vital signs)
were not required, 46 AEs encompassing 368 data points
would be eliminated. If reports of signs and symptoms of
conditions and syndromes were not required, 16 additional
AEs encompassing 128 data points would be eliminated.
